Faron begins enrolment for Phase III trial of Traumakine to treat respiratory disease in Japan

Faron Pharmaceuticals has reported that its Japanese licensing partner Maruishi Pharmaceutical has recruited the first patient in the Phase III pivotal clinical trial for the treatment of acute respiratory distress syndrome (ARDS) with FP-1201-lyo (a …

Source: Drug Development Technology - October 25, 2016 Category: Pharmaceuticals Source Type: news